Immune checkpoint inhibitors (ICIs), which target key inhibitory pathways such as PD-1/PD-L1 and CTLA-4, have revolutionized cancer immunotherapy by reinstating T-cell activity and overcoming immune evasion mechanisms (1). This evidence concerns the gene CTLA4 and cancer.